Rankings
▼
Calendar
SAVA
Cassava Sciences, Inc.
$116M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$89M
Operating Income
-$106M
Net Income
-$97M
EPS (Diluted)
$-2.32
Cash Flow
Operating Cash Flow
-$82M
Free Cash Flow
-$82M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$152M
Total Liabilities
$14M
Stockholders' Equity
$137M
Cash & Equivalents
$121M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$89M
-$68M
-31.4%
Operating Income
-$106M
-$80M
-32.4%
Net Income
-$97M
-$76M
-27.5%
← Q4 2022
All Quarters
Q1 2023 →
SAVA FY 2023 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena